{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:13:37Z","timestamp":1790313217289,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,10,2]],"date-time":"2017-10-02T00:00:00Z","timestamp":1506902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,10,2]],"date-time":"2017-10-02T00:00:00Z","timestamp":1506902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008533","name":"Case Comprehensive Cancer Center, Case Western Reserve University","doi-asserted-by":"publisher","award":["Early Phase Clinical Research Support"],"award-info":[{"award-number":["Early Phase Clinical Research Support"]}],"id":[{"id":"10.13039\/100008533","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University Hospitals Cleveland Medical Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10637-017-0515-3","type":"journal-article","created":{"date-parts":[[2017,10,2]],"date-time":"2017-10-02T04:40:31Z","timestamp":1506919231000},"page":"435-441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9515-0498","authenticated-orcid":false,"given":"Priyanka","family":"Bhateja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,2]]},"reference":[{"issue":"1","key":"515_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"515_CR2","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543\u20133551","journal-title":"J Clin Oncol"},{"issue":"43","key":"515_CR3","first-page":"204","volume":"8","author":"AG Favaretto","year":"2009","unstructured":"Favaretto AG, Pasello G, Magro C (2009) Second and third line treatment in advanced non-small cell lung cancer. Discov Med 8(43):204\u2013209","journal-title":"Discov Med"},{"issue":"2","key":"515_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123\u2013132","journal-title":"N Engl J Med"},{"key":"515_CR5","doi-asserted-by":"crossref","unstructured":"Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18(12):2354\u20132362. In","DOI":"10.1200\/JCO.2000.18.12.2354"},{"key":"515_CR6","doi-asserted-by":"crossref","unstructured":"Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589\u22121597. In","DOI":"10.1200\/JCO.2004.08.163"},{"key":"515_CR7","doi-asserted-by":"crossref","unstructured":"Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095\u20132103. In","DOI":"10.1200\/JCO.2000.18.10.2095"},{"issue":"17","key":"515_CR8","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 373(17):1627\u20131639","journal-title":"N Engl J Med"},{"issue":"2","key":"515_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373(2):123\u2013135","journal-title":"N Engl J Med"},{"issue":"3","key":"515_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239\u2013246","journal-title":"Lancet Oncol"},{"key":"515_CR11","doi-asserted-by":"crossref","unstructured":"Wu YL, Zhou C, Liam CK et al (2015) First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label. ENSURE study Ann Oncol 26(9):1883\u20131889","DOI":"10.1093\/annonc\/mdv270"},{"issue":"8","key":"515_CR12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735\u2013742","journal-title":"Lancet Oncol"},{"issue":"9","key":"515_CR13","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/annonc\/mdv276","volume":"26","author":"C Zhou","year":"2015","unstructured":"Zhou C, Wu YL, Chen G et al (2015) Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol 26(9):1877\u20131883","journal-title":"Ann Oncol"},{"key":"515_CR14","doi-asserted-by":"crossref","unstructured":"Tumors Resistant to EGFR Inhibitors Can Arise via Different Mechanisms. Cancer Discov. 2016;6(3):228","DOI":"10.1158\/2159-8290.CD-RW2016-023"},{"issue":"40","key":"515_CR15","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.18632\/oncotarget.3956","volume":"6","author":"E Galvani","year":"2015","unstructured":"Galvani E, Sun J, Leon LG et al (2015) NF-\u03baB drives acquired resistance to a novel mutant-selective EGFR inhibitor. Oncotarget 6(40):42717\u201342732","journal-title":"Oncotarget"},{"issue":"18","key":"515_CR16","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"PA J\u00e4nne","year":"2015","unstructured":"J\u00e4nne PA, Yang JC, Kim DW et al (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372(18):1689\u20131699","journal-title":"N Engl J Med"},{"issue":"5","key":"515_CR17","first-page":"411","volume":"4","author":"Y Lin","year":"2014","unstructured":"Lin Y, Wang X, Jin H (2014) EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 4(5):411\u2013435","journal-title":"Am J Cancer Res"},{"key":"515_CR18","volume-title":"Kanda S","author":"S Noda","year":"2016","unstructured":"Noda S (2016) Kanda S. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer, Expert Rev Respir Med"},{"issue":"6","key":"515_CR19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1056\/NEJMc1506831","volume":"373","author":"LV Sequist","year":"2015","unstructured":"Sequist LV, Rolfe L, Allen AR (2015) Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 373(6):578\u2013579","journal-title":"N Engl J Med"},{"issue":"10","key":"515_CR20","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","volume":"2","author":"K Takezawa","year":"2012","unstructured":"Takezawa K, Pirazzoli V, Arcila ME et al (2012) HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2(10):922\u2013933","journal-title":"Cancer Discov"},{"key":"515_CR21","doi-asserted-by":"crossref","unstructured":"Wu SG, Liu YN, Tsai MF et al (2016) The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget 7(11):12404\u201312414","DOI":"10.18632\/oncotarget.7189"},{"issue":"7339","key":"515_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature09870","volume":"471","author":"TG Bivona","year":"2011","unstructured":"Bivona TG, Hieronymus H, Parker J et al (2011) FAS and NF-\u03baB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471(7339):523\u2013526","journal-title":"Nature"},{"issue":"9","key":"515_CR23","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-14-0013","volume":"13","author":"JK Dermawan","year":"2014","unstructured":"Dermawan JK, Gurova K, Pink J et al (2014) Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-\u03baB, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther 13(9):2203\u20132214","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"515_CR24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","volume":"11","author":"F Cappuzzo","year":"2010","unstructured":"Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11(6):521\u2013529","journal-title":"Lancet Oncol"},{"issue":"3","key":"515_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(11)70385-0","volume":"13","author":"T Ciuleanu","year":"2012","unstructured":"Ciuleanu T, Stelmakh L, Cicenas S et al (2012) Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 13(3):300\u2013308","journal-title":"Lancet Oncol"},{"issue":"2","key":"515_CR26","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/annonc\/mdr125","volume":"23","author":"B Coudert","year":"2012","unstructured":"Coudert B, Ciuleanu T, Park K et al (2012) Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 23(2):388\u2013394","journal-title":"Ann Oncol"},{"issue":"6","key":"515_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.ejca.2012.11.006","volume":"49","author":"E Juh\u00e1sz","year":"2013","unstructured":"Juh\u00e1sz E, Kim JH, Klingelschmitt G, Walzer S (2013) Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. Eur J Cancer 49(6):1205\u20131215","journal-title":"Eur J Cancer"},{"issue":"2","key":"515_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.lungcan.2012.03.012","volume":"77","author":"YL Wu","year":"2012","unstructured":"Wu YL, Kim JH, Park K, Zaatar A, Klingelschmitt G, Ng C (2012) Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study. Lung Cancer 77(2):339\u2013345","journal-title":"Lung Cancer"},{"key":"515_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.lungcan.2016.10.007","volume":"102","author":"S Cic\u00e8nas","year":"2016","unstructured":"Cic\u00e8nas S, Geater SL, Petrov P et al (2016) Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Lung Cancer 102:30\u201337","journal-title":"Lung Cancer"},{"issue":"48","key":"515_CR30","doi-asserted-by":"publisher","first-page":"17448","DOI":"10.1073\/pnas.0508888102","volume":"102","author":"KV Gurova","year":"2005","unstructured":"Gurova KV, Hill JE, Guo C et al (2005) Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A 102(48):17448\u201317453","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"515_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.celrep.2015.03.012","volume":"11","author":"CM Blakely","year":"2015","unstructured":"Blakely CM, Pazarentzos E, Olivas V et al (2015) NF-\u03baB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep 11(1):98\u2013110","journal-title":"Cell Rep"},{"issue":"32","key":"515_CR32","doi-asserted-by":"publisher","first-page":"11721","DOI":"10.1073\/pnas.1412390111","volume":"111","author":"S De","year":"2014","unstructured":"De S, Dermawan JK, Stark GR (2014) EGF receptor uses SOS1 to drive constitutive activation of NF\u03baB in cancer cells. Proc Natl Acad Sci U S A 111(32):11721\u201311726","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"515_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/archinte.1954.00250010137011","volume":"94","author":"EL Dubois","year":"1954","unstructured":"Dubois EL (1954) Quinacrine (atabrine) in treatment of systemic and discoid lupus erythematosus. AMA Arch Intern Med 94(1):131\u2013141","journal-title":"AMA Arch Intern Med"},{"issue":"1","key":"515_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3109\/rhe1.1958.4.issue-1-4.04","volume":"4","author":"A Engeset","year":"1958","unstructured":"Engeset A (1958) Treatment of rheumatoid arthritis with quinacrine and chloroquine. Acta Rheumatol Scand 4(1):28\u201339","journal-title":"Acta Rheumatol Scand"},{"key":"515_CR35","first-page":"65","volume":"78","author":"Plasma quinacrine concentration as a function of dosage and environment","year":"1948","unstructured":"Plasma quinacrine concentration as a function of dosage and environment (1948) Joint Report of the Armoured Medical Research Laboratories and The Commission on Tropical Diseases, US Army. Arch Intern Med 78:65\u2013106","journal-title":"Arch Intern Med"},{"issue":"2","key":"515_CR36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/00034983.1988.11812216","volume":"82","author":"S Looareesuwan","year":"1988","unstructured":"Looareesuwan S, Phillips RE, Edwards G et al (1988) Mepacrine accumulation during treatment of chloroquine-resistant falciparum malaria. Ann Trop Med Parasitol 82(2):107\u2013112","journal-title":"Ann Trop Med Parasitol"},{"issue":"3","key":"515_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.lungcan.2003.10.010","volume":"43","author":"A Argiris","year":"2004","unstructured":"Argiris A, Mittal N (2004) Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 43(3):317\u2013322","journal-title":"Lung Cancer"},{"key":"515_CR38","doi-asserted-by":"crossref","unstructured":"Gasparian AV, Burkhart CA, Purmal AA, et al. Curaxins: anticancer compounds that simultaneously suppress NF-\u03baB and activate p53 by targeting FACT. Sci Transl Med. 2011;3(9 ):95ra74","DOI":"10.1126\/scitranslmed.3002530"},{"issue":"8","key":"515_CR39","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1158\/0008-5472.CAN-15-2162","volume":"76","author":"JK Dermawan","year":"2016","unstructured":"Dermawan JK, Hitomi M, Silver DJ et al (2016) Pharmacological targeting of the histone chaperone complex FACT preferential eliminates glioblastoma stem cells and prolongs survival in preclinical models. Cancer Res 76(8):2432\u20132442","journal-title":"Cancer Res"},{"key":"515_CR40","doi-asserted-by":"crossref","unstructured":"Sharma N, Dermawan J, Purmal AA, et al. Targeting FACT complex with CBL0137 to overcome acquired resistance to EGFR-TKI in lung adenocarcinoma. Cancer Res. 2016;76(14 Suppl): Abstract nr 3036","DOI":"10.1158\/1538-7445.AM2016-3036"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0515-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:20:03Z","timestamp":1678558803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0515-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,2]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["515"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0515-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,2]]},"assertion":[{"value":"8 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Afshin Dowlati received research grants from Bristol-Myers Squibb, Abbvie, AstraZeneca, Novartis Pharma and Roche-Peru and consulting role for Ariad pharmaceuticals. Neelesh Sharma received research funding from Incuron during the study and is currently employed by Novartis Pharma. Priyanka Bhateja declares that she has no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}